CTLA4 and hepatocellular carcinoma: Notably, the immunotherapeutic combination of the PD-1 inhibitor Opdivo (nivolumab) and the CTLA-4-targeting antibody Yervoy (ipilimumab) represents the first approved dual immune checkpoint inhibitor regimen for the management of advanced HCC populations (4).